Biosimilar safety factors in clinical practice

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 6, 2015, Pages S9-S15

  Reinisch, Walter ^a,b   Smolen, Josef ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

^d Neurological Center Rosenhuegel   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; INFLIXIMAB; METHOTREXATE; NEUTRALIZING ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; DRUG FORMULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG NOMENCLATURE; DRUG PACKAGING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INFLAMMATORY BOWEL DISEASE; NONHUMAN; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG INDUSTRY; EUROPE; INFLAMMATION; LEGISLATION AND JURISPRUDENCE; ORGANIZATION AND MANAGEMENT; PATIENT CARE; PATIENT SAFETY; STANDARDS; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; EUROPE; GUIDELINES AS TOPIC; HUMANS; INFLAMMATION; PATIENT CARE; PATIENT SAFETY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84955611800     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2015.04.005     Document Type: Article

References (59)

1. Scheinberg, M.A., Kay, J., The advent of biosimilar therapies in rheumatology—“O brave new world”. Nat Rev Rheumatol 8 (2012), 430–436.
2. Kay, J., Smolen, J.S., Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 72 (2013), 1589–1593.
3. Dorner, T., Strand, V., Castaneda-Hernandez, G., Ferraccioli, G., Isaacs, J.D., Kvien, T.K., et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72 (2013), 322–328.
4. Strober, B.E., Armour, K., Romiti, R., Smith, C., Tebbey, P.W., Menter, A., et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. J Am Acad Dermatol 66 (2012), 317–322.
5. European Medicines Agency. Assessment report. Inflectra, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002778/WC500151490.pdf〉; 2013 [accessed 08.04.14].
6. European Medicines Agency. Assessment report. Remsima, 〈http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf〉; 2013 [accessed 09.04.14].
7. Epirus’ Remicade biosimilar receives final approvals in India. Epirus Biopharmaceuticals, 〈http://ir.epirusbiopharma.com/releasedetail.cfm?releaseid=870875〉; 2014 [accessed 18.12.14].
8. Celltrion's Remsima (infliximab) receives marketing approval in Japan. Celltrion, 〈http://www.celltrion.com/en/company/notice_view.asp?idx=451&code=ennews&intNowPage=1&menu_num=&align_year=all〉; 2014 [accessed 18.12.14].
9. Celltrion's Remsima receives Turkey Ministry of Health approval. Celltrion, 〈http://www.celltrion.com/en/company/notice_view.asp?idx=452&code=ennews&intNowPage=1&menu_num=&align_year=all〉; 2014 [accessed 18.12.14].
10. Rickwood S, Di Biase S. IMS Health. Searching for terra firma in the biosimilars and non-original biologics market. Insights for the coming decade of change. 〈http://www.imshealth.com/cds/imshealth/Global/Content/Healthcare/Life%20Sciences%20Solutions/Generics/IMSH_Biosimilars_WP.pdf〉; 2013 [accessed 02.04.14].
11. IMS Institute for Health Informatics. Assessing biosimilar uptake and competition in European markets. I, 〈http://www.imshealth.com/imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Insights/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf〉; 2014 [accessed 08.12.14].
12. Schellekens, H., Ryff, J.C., ‘Biogenerics’: the off-patent biotech products. Trends Pharmacol Sci 23 (2002), 119–121.
13. Jiang, H., Wu, S.L., Karger, B.L., Hancock, W.S., Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen activator. Anal Chem 82 (2010), 6154–6162.
14. ®) with those of an alleged biosimilar. Front Pharmacol, 5, 2014, 7.
15. Declerck, P.J., Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther 13 (2013), 153–156.
16. Nash, P., Nayiager, S., Genovese, M.C., Kivitz, A.J., Oelle, K., Ludivico, C., et al. Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) 65 (2013), 718–728.
17. European Medicines Agency. Guideline on similar biological medical products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf〉; 2013 [accessed 14.01.14].
18. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies- non-clinical and clinical issues, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128686.pdf〉; 2012 [accessed 19.12.13].
19. US Food and Drug Administration. Guidance for industry. Scientific considerations in demonstrating biosimilarity to a reference product, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf〉; 2012 [accessed 21.05.14].
20. US Food and Drug Administration. Guidance for industry. Assay development for immunogenicity testing of therapeutic proteins, 〈http://www.fda.gov/downloads/Drugs/…/Guidances/UCM192750.pdf〉; 2009 [accessed 14.04.14].
21. Patient Protection and Affordable Care Act. Congress of the United States of America, 〈http://www.gpo.gov/fdsys/pkg/PLAW-111publ148/pdf/PLAW-111publ148.pdf〉; 2010 [accessed 18.12.13].
22. Schellekens, H., Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 1 (2002), 457–462.
23. Cai, X.Y., Thomas, J., Cullen, C., Gouty, D., Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development. Bioanalysis 4 (2012), 2169–2177.
24. Purcell, R.T., Lockey, R.F., Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 18 (2008), 335–342.
25. European Medicines Agency. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128688.pdf〉; 2012 [accessed 15.01.14].
26. US Food and Drug Administration. Guidance for industry. Immunogenicity assessment for therapeutic protein products, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM338856.pdf〉; 2013 [accessed 14.04.14].
27. Strand, V., Cronstein, B., Biosimilars: how similar?. Intern Med J 44 (2014), 218–223.
28. Kanter, J., Feldman, R., Understanding and incentivizing biosimilars. Hastings Law J 64 (2012), 57–82.
29. Mellstedt, H., Niederwieser, D., Ludwig, H., The challenge of biosimilars. Ann Oncol 19 (2008), 411–419.
30. Garces, S., Demengeot, J., Benito-Garcia, E., The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 72 (2013), 1947–1955.
31. Wolbink, G.J., Vis, M., Lems, W., Voskuyl, A.E., deGroot, E., Nurmohamed, M.T., et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006), 711–715.
32. Krieckaert, C.L., Jamnitski, A., Nurmohamed, M.T., Kostense, P.J., Boers, M., Wolbink, G., Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity. Arthritis Rheum 64 (2012), 3850–3855.
33. Maini, R.N., Breedveld, F.C., Kalden, J.R., Smolen, J.S., Davis, D., Macfarlane, J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 (1998), 1552–1563.
34. Burmester, G.R., Kivitz, A.J., Kupper, H., Arulmani, U., Florentinus, S., Goss, S.L., et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis, 2014 〈http://dx.doi.org/10.1136/annrheumdis-2013-204769〉.
35. ClinicalTrials gov. A study to determine the effect of methotrexate (MTX) dose on clinical outcome and ultrasonographic signs in subjects with moderately to severely active rheumatoid arthritis (RA) treated with adalimumab (MUSICA), 〈https://clinicaltrials.gov/ct2/show/results/NCT01185288?sect=X7#limit〉; 2014 [accessed 18.12.14].
36. Kuhlmann, M., Covic, A., The protein science of biosimilars. Nephrol Dial Transplant 21 (2006), v4–v8.
37. Schiestl, M., Stangler, T., Torella, C., Cepeljnik, T., Toll, H., Grau, R., Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29 (2011), 310–312.
38. US Food and Drug Administration. Guidance for industry. Quality considerations in demonstrating biosimilarity to a reference protein product, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf〉; 2012 [accessed 21.05.14].
39. US Food and Drug Administration. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product, 〈http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf〉; 2014 [accessed 19.05.14].
40. Giezen TJ, Schneider CK. Safety assessment of biosimilars in Europe: a regulatory perspective, 〈http://gabi-journal.net/safety-assessment-of-biosimilars-in-europe-a-regulatory-perspective.html〉, 2014 [accessed 23.12.14].
41. Park, W., Hrycaj, P., Jeka, S., Kovalenko, V., Lysenko, G., Miranda, P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72 (2013), 1605–1612.
42. Yoo, D.H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72 (2013), 1613–1620.
43. Yoo D, Park W, Miranda P, Piotrowski M, Ramiterre E, Shevchuk S, et al. Inhibition of radiographic progression and its association with clinical parameters in RA patients treated with CT-P13 and innovator infliximab in PLANETRA study. Paper presented at 2014 Annual European Congress of Rheumatology. Paris, France; June 11–14, 2014.
44. McKeage, K., A review of CT-P13: an infliximab biosimilar. BioDrugs, 2014 〈http://dx.doi.org/10.1007/s40259-014-0094-1〉.
45. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, 〈http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf〉; 2007 [accessed 14.04.14].
46. US Food and Drug Administration. Guidance for industry. Good pharmacovigilance practices and pharmacoepidemiologic assessment, 〈http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126834.pdf〉; 2005 [accessed 01.05.14].
47. The future of biosimilar use and regulation in Latin America. GaBI Online, 〈http://www.gabionline.net/Biosimilars/Research/The-future-of-biosimilar-use-and-regulation-in-Latin-America〉; 2014 [accessed 22.12.14].
48. Calvo B, Zuniga L. InTech. Risk management plan and pharmacovigilance system- biopharmaceuticals: biosimilars, 〈http://www.intechopen.com/books/risk-management-trends/risk-managementplan-and-pharmacovigilance-system-biopharmaceuticals-biosimilars〉; 2011 [accessed 01.05.14].
49. US Food and Drug Administration. Guidance for industry: format and content of proposed Risk Evaluation and Mitigation Strategies (REMS), REMS assessments, and proposed REMS modifications, 〈http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM184128.pdf〉; 2009 [accessed 19.12.14].
50. Genovese, M.C., Covarrubias, A., Leon, G., Mysler, E., Keisermann, M., Valente, R., et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 63 (2011), 2854–2864.
51. Keystone, E.C., Kremer, J.M., Russell, A., Box, J., Abud-Mendoza, C., Elizondo, M.G., et al. Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71 (2012), 857–861.
52. Zhang, X., Chen, Y.C., Fettner, S., Rowell, L., Gott, T., Grimsey, P., et al. Pharmacokinetics and pharmacodynamics of tocilizumab after subcutaneous administration in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 51 (2013), 620–630.
53. Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73 (2014), 69–74.
54. Ogata, A., Tanimura, K., Sugimoto, T., Inoue, H., Urata, Y., Matsubara, T., et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66 (2014), 344–354.
55. State laws and legislation related to biologic medications and substitution of biosimilars. National Conference of State Legislatures, 〈http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx〉; 2014 [accessed 03.09.14].
56. World Health Organization. 57th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 22–24 October 2013. Executive summary, 〈http://www.who.int/medicines/services/inn/57th_Executive_Summary.pdf?ua=1〉; 2013 [accessed 02.05.14].
57. US Food and Drug Administration. How FDA reviews proposed drug names, 〈http://www.fda.gov/downloads/Drugs/DrugSafety/MedicationErrors/ucm080867.pdf〉; 2014 [accessed 02.05.14].
58. World Health Organization. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances, Geneva, 15–17 April 2013. Executive summary, 〈http://www.who.int/medicines/services/inn/56th_Executive_Summary.pdf?ua=1〉; 2013 [accessed 02.05.14].
59. World Health Organization. Biological qualifier. An INN proposal, 〈http://www.who.int/medicines/services/inn/bq_innproposal201407.pdf〉; 2014 [accessed 22.12.14].